TY - JOUR
T1 - Immune-based therapies for traumatic brain injury
T2 - Insights from pre-clinical studies
AU - Machado, Caroline Amaral
AU - Silva, Ana Cristina Simões E.
AU - de Miranda, Amanda Silva
AU - Cordeiro, Thiago Macedo E.
AU - Ferreira, Rodrigo Novaes
AU - de Souza, Leonardo Cruz
AU - Teixeira, Antônio Lúcio
AU - de Miranda, Aline Silva
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Traumatic Brain Injury (TBI) is a major public health problem. It is the leading cause of death and disability, especially among children and young adults. The neurobiology basis underlying TBI pathophysiology remains to be fully revealed. Over the past years, emerging evidence has supported the hypothesis that TBI is an inflammatory based condition, paving the way for the development of potential therapeutic targets. There is no treatment capable to prevent or minimize TBI-associated outcomes. Therefore, the search for effective therapies is a priority goal. In this context, animal models have become valuable tools to study molecular and cellular mechanisms involved in TBI pathogenesis as well as novel treatments. Herein, we discuss therapeutic strategies to treat TBI focused on immunomodulatory and/or anti-inflammatory approaches in the pre-clinical setting.
AB - Traumatic Brain Injury (TBI) is a major public health problem. It is the leading cause of death and disability, especially among children and young adults. The neurobiology basis underlying TBI pathophysiology remains to be fully revealed. Over the past years, emerging evidence has supported the hypothesis that TBI is an inflammatory based condition, paving the way for the development of potential therapeutic targets. There is no treatment capable to prevent or minimize TBI-associated outcomes. Therefore, the search for effective therapies is a priority goal. In this context, animal models have become valuable tools to study molecular and cellular mechanisms involved in TBI pathogenesis as well as novel treatments. Herein, we discuss therapeutic strategies to treat TBI focused on immunomodulatory and/or anti-inflammatory approaches in the pre-clinical setting.
KW - Anti-inflammatory
KW - Immunomodulatory agents
KW - Inflammation
KW - Pathogenesis
KW - Traumatic brain injury
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85076016399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076016399&partnerID=8YFLogxK
U2 - 10.2174/0929867326666190710173234
DO - 10.2174/0929867326666190710173234
M3 - Review article
C2 - 31291871
AN - SCOPUS:85076016399
SN - 0929-8673
VL - 27
SP - 5374
EP - 5402
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 32
ER -